Evaluate the Safety and Efficacy of Quadrivalent Influenza in Real-world Situations.

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2021
To evaluate the inter-batch consistency (CI) of quadrivalent influenza vaccine (split virion) among healthy people aged 18-59 years; Secondly, to evaluate the safety and immunogenicity of quadrivalent influenza vaccine (split virion) in the expanded population aged 3 years and above, in order to observe the rare adverse reaction of 1‰.
Epistemonikos ID: 16d8c56c6d5f9a93d802258188cb84a860f7edf1
First added on: May 15, 2024